Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 3
1995 2
1996 2
1997 2
1998 2
1999 2
2000 4
2001 5
2002 7
2003 13
2004 10
2005 15
2006 9
2007 6
2008 3
2009 5
2010 5
2011 3
2014 1
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 14506198

102 results

Results by year

Filters applied: . Clear all
Page 1
Epratuzumab: targeting B-cell malignancies through CD22.
Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP. Coleman M, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3991S-4S. Clin Cancer Res. 2003. PMID: 14506198 Review.
CD22 as a target of passive immunotherapy.
Cesano A, Gayko U. Cesano A, et al. Semin Oncol. 2003 Apr;30(2):253-7. doi: 10.1053/sonc.2003.50057. Semin Oncol. 2003. PMID: 12720147 Review.
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM. Leonard JP, et al. Clin Cancer Res. 2004 Aug 15;10(16):5327-34. doi: 10.1158/1078-0432.CCR-04-0294. Clin Cancer Res. 2004. PMID: 15328168 Clinical Trial.
102 results